KRLS-004 is under clinical development by Kirilys Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KRLS-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KRLS-004 overview
KRLS-004 (ASN-004) is under development for the treatment of solid tumors including breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, liver cancer, renal carcinomas and head and neck squamous cell carcinoma. The drug candidate is an antibody-drug conjugate (ADC) which acts by targeting 5T4-oncofetal glycoprotein. It is developed based on fleximer linker (Dolaflexin) technology. It is administered through intravenous route.
It was under development for the treatment of gastric cancer and cervical epidermoid tumor.
Kirilys Therapeutics overview
Kirilys Therapeutics is a pharmaceuticals and healthcare company which is engaged in the research and development of therapeutic treatments for cancer disease. The company is headquartered in United States.
For a complete picture of KRLS-004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
